These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 5067490

  • 21. [Effect of BAY a 1040 on renal function in hypertension].
    Klütsch K, Schmidt P, Grosswendt J.
    Arzneimittelforschung; 1972 Feb; 22(2):377-80. PubMed ID: 5067491
    [No Abstract] [Full Text] [Related]

  • 22. [Therapy of ischemic heart diseases with carbochromen].
    Savenkov PM, Arsukuni RO, Pflug C.
    Arzneimittelforschung; 1970 Mar; 20():461-2. PubMed ID: 5468731
    [No Abstract] [Full Text] [Related]

  • 23. [The mechanism of coronary dilatating action of nifedipine].
    Kosche F, Raff WK, Lochner W.
    Arzneimittelforschung; 1972 Jan; 22(1):39-42. PubMed ID: 5066996
    [No Abstract] [Full Text] [Related]

  • 24. Inotropic effects of Nifedipine: a new coronary dilating agent.
    Strauer BE.
    Int J Clin Pharmacol; 1974 Mar; 9(2):101-7. PubMed ID: 4827553
    [No Abstract] [Full Text] [Related]

  • 25. The effects of a new coronary vasocilator (BAY-a-1040, Nifedipine) on the coronary and systemic haemodynamics in the anaesthetized dog.
    Maxwell GM, Rencis V.
    Aust J Exp Biol Med Sci; 1973 Feb; 51(1):117-20. PubMed ID: 4699546
    [No Abstract] [Full Text] [Related]

  • 26. [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].
    Grün G, Fleckenstein A.
    Arzneimittelforschung; 1972 Feb; 22(2):334-44. PubMed ID: 4623697
    [No Abstract] [Full Text] [Related]

  • 27. [Effects of octapressin on the general and coronary circulation in anesthetized, closed chest dogs].
    Strauer BE, Reploh HD, Cott L, Tauchert M, Bretschneider HJ.
    Arztl Forsch; 1969 Jul 10; 23(7):227-35. PubMed ID: 5820305
    [No Abstract] [Full Text] [Related]

  • 28. Hemodynamic effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) at rest and during exercise with special respect to the pulmonary circulation.
    Koch G.
    Arzneimittelforschung; 1971 Jan 10; 21(1):57-61. PubMed ID: 5108382
    [No Abstract] [Full Text] [Related]

  • 29. Systemic and coronary hemodynamic effects of 3-(beta-diethylamino-ethyl)-4-methyl-7-carbethoxy-methoxy-2-oxo-(1,2-chromene)-hydrochloride (Intensain, A-27053).
    Rowe GG, McKenna DH, Sialer S, Corliss RJ.
    Vasc Dis; 1967 Jun 10; 4(3):183-90. PubMed ID: 6028828
    [No Abstract] [Full Text] [Related]

  • 30. Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.
    Vogt A, Neuhaus KL, Kreuzer H.
    Arzneimittelforschung; 1980 Jun 10; 30(12):2162-4. PubMed ID: 7194078
    [Abstract] [Full Text] [Related]

  • 31. [Development of coronary collaterals following oral long-term therapy with nifedipine. Increased survival time following experimental coronary occlusion].
    van Ackern K, Braasch W, Brückner UB, Heger W, Schmier J.
    Arzneimittelforschung; 1974 Oct 10; 24(10):1577-81. PubMed ID: 4479765
    [No Abstract] [Full Text] [Related]

  • 32. Haemodynamic effects of vasoactive agents following chronic state of high cardiac output in anaesthetized rats.
    Guo L, Tabrizchi R.
    Eur J Pharmacol; 2008 May 31; 586(1-3):266-74. PubMed ID: 18367170
    [Abstract] [Full Text] [Related]

  • 33. Effects of various coronary vasodilators on myocardial oxygen consumption.
    Oguro K, Kubota K, Kimura T, Hashimoto K.
    Jpn J Pharmacol; 1973 Aug 31; 23(4):459-66. PubMed ID: 4202125
    [No Abstract] [Full Text] [Related]

  • 34. Effects of selective coronary hypotension and nitroglycerin or Bay a 1040 on the distribution of Rb86 clearance in the canine heart.
    Nakamura M, Eto Y, Hamanaka N, Kuroiwa A, Tomoike H.
    Cardiovasc Res; 1973 Nov 31; 7(6):777-88. PubMed ID: 4206541
    [No Abstract] [Full Text] [Related]

  • 35. Regional blood flow and cardiac responses to hydralazine.
    Spokas EG, Wang HH.
    J Pharmacol Exp Ther; 1980 Feb 31; 212(2):294-303. PubMed ID: 7351643
    [No Abstract] [Full Text] [Related]

  • 36. Cardiovascular effects of beta blockade with inderal in normal subjects.
    Gebhardt W, König K, Büchner C.
    Int Z Klin Pharmakol Ther Toxikol; 1968 Apr 31; 1(4):289-95. PubMed ID: 4882204
    [No Abstract] [Full Text] [Related]

  • 37. [Promotion of organ circulation by raubasine].
    Dietmann K.
    Arzneimittelforschung; 1967 Aug 31; 17(8):969-75. PubMed ID: 5632071
    [No Abstract] [Full Text] [Related]

  • 38. The clinical effect of 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine (BAY a 1040) on angina pectoris evaluated by sequential analysis.
    Kimura E, Mabuchi G, Kikuchi H.
    Arzneimittelforschung; 1972 Feb 31; 22(2):365-7. PubMed ID: 4623700
    [No Abstract] [Full Text] [Related]

  • 39. Clinical experience with a new coronary-active substance (BAY 1 1040).
    Kobayashi T, Ito Y, Tawara I.
    Arzneimittelforschung; 1972 Feb 31; 22(2):380-9. PubMed ID: 5067492
    [No Abstract] [Full Text] [Related]

  • 40. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93).
    Takenaka T, Usuda S, Nomura T, Maeno H, Sado T.
    Arzneimittelforschung; 1976 Feb 31; 26(12):2172-8. PubMed ID: 1037267
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.